6 O
ADVERSE O
REACTIONS O
The O
following O
important O
adverse O
reactions O
are O
also O
described O
elsewhere O
in O
the O
labeling O
: O
* O
Increased O
mortality O
in O
patients O
with O
acute O
critical O
illness O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Fatalities O
in O
children O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Neoplasms B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Glucose B-OSE_Labeled_AE
intolerance I-OSE_Labeled_AE
and O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Intracranial B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Severe O
hypersensitivity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Hypoadrenalism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Hypothyroidism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Slipped B-OSE_Labeled_AE
capital I-OSE_Labeled_AE
femoral I-OSE_Labeled_AE
epiphysis I-OSE_Labeled_AE
in O
pediatric O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Progression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
preexisting I-OSE_Labeled_AE
scoliosis I-OSE_Labeled_AE
in O
pediatric O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
and O
cardiovascular B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
in O
patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Lipoatrophy B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Pancreatitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
EXCERPT O
: O
Other O
common O
somatropin-related O
adverse O
reactions O
include O
injection O
site O
reactions/rashes O
and O
lipoatrophy O
( O
6.1 O
) O
and O
headaches O
( O
6.3 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
Inc O
. O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
during O
the O
clinical O
trials O
performed O
with O
one O
somatropin O
formulation O
can O
not O
always O
be O
directly O
compared O
to O
the O
rates O
observed O
during O
the O
clinical O
trials O
performed O
with O
a O
second O
somatropin O
formulation O
, O
and O
may O
not O
reflect O
the O
adverse O
reaction O
rates O
observed O
in O
practice O
. O

Clinical O
Trials O
in O
children O
with O
GHD O
In O
clinical O
studies O
with O
GENOTROPIN O
in O
pediatric O
GHD B-Not_AE_Candidate
patients O
, O
the O
following O
events O
were O
reported O
infrequently O
: O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
pain B-OSE_Labeled_AE
or O
burning O
associated O
with I-OSE_Labeled_AE
the I-OSE_Labeled_AE
injection I-OSE_Labeled_AE
, O
fibrosis O
, O
nodules O
, O
rash O
, O
inflammation O
, O
pigmentation O
, O
or O
bleeding O
; O
lipoatrophy B-OSE_Labeled_AE
; O
headache B-OSE_Labeled_AE
; O
hematuria B-OSE_Labeled_AE
; O
hypothyroidism B-OSE_Labeled_AE
; O
and O
mild O
hyperglycemia B-OSE_Labeled_AE
. O

Clinical O
Trials O
in O
PWS O
In O
two O
clinical O
studies O
with O
GENOTROPIN O
in O
pediatric O
patients O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
the O
following O
drug-related O
events O
were O
reported O
: O
edema B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
benign B-OSE_Labeled_AE
intracranial I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
hair B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
myalgia B-OSE_Labeled_AE
. O

Clinical O
Trials O
in O
children O
with O
SGA O
In O
clinical O
studies O
of O
273 O
pediatric O
patients O
born O
small B-Not_AE_Candidate
for I-Not_AE_Candidate
gestational I-Not_AE_Candidate
age I-Not_AE_Candidate
treated O
with O
GENOTROPIN O
, O
the O
following O
clinically O
significant O
events O
were O
reported O
: O
mild O
transient O
hyperglycemia B-OSE_Labeled_AE
, O
one O
patient O
with O
benign B-OSE_Labeled_AE
intracranial I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
two O
patients O
with O
central B-OSE_Labeled_AE
precocious I-OSE_Labeled_AE
puberty I-OSE_Labeled_AE
, O
two O
patients O
with O
jaw B-OSE_Labeled_AE
prominence I-OSE_Labeled_AE
, O
and O
several O
patients O
with O
aggravation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
preexisting I-OSE_Labeled_AE
scoliosis I-OSE_Labeled_AE
, O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
and O
self-limited O
progression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pigmented I-OSE_Labeled_AE
nevi I-OSE_Labeled_AE
. O

Anti B-NonOSE_AE
- I-NonOSE_AE
hGH I-NonOSE_AE
antibodies I-NonOSE_AE
were O
not O
detected O
in O
any O
of O
the O
patients O
treated O
with O
GENOTROPIN O
. O

Clinical O
Trials O
in O
children O
with O
Turner O
Syndrome O
In O
two O
clinical O
studies O
with O
GENOTROPIN O
in O
pediatric O
patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
the O
most O
frequently O
reported O
adverse O
events O
were O
respiratory B-OSE_Labeled_AE
illnesses I-OSE_Labeled_AE
( O
influenza B-OSE_Labeled_AE
, O
tonsillitis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
) O
, O
joint B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

The O
only O
treatment-related O
adverse O
event O
that O
occurred O
in O
more O
than O
1 O
patient O
was O
joint B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

Clinical O
Trials O
in O
children O
with O
Idiopathic O
Short O
Stature O
In O
two O
open-label O
clinical O
studies O
with O
GENOTROPIN O
in O
pediatric O
patients O
with O
ISS B-Not_AE_Candidate
, O
the O
most O
commonly O
encountered O
adverse O
events O
include O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
tonsillitis B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
headaches B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
fracture B-OSE_Labeled_AE
, O
altered B-OSE_Labeled_AE
mood I-OSE_Labeled_AE
, O
and O
arthralgia B-OSE_Labeled_AE
. O

In O
one O
of O
the O
two O
studies O
, O
during O
GENOTROPIN O
treatment O
, O
the O
mean O
IGF-1 O
standard O
deviation O
( O
SD O
) O
scores O
were O
maintained O
in O
the O
normal O
range O
. O

IGF-1 O
SD O
scores O
above O
+2 O
SD O
were O
observed O
as O
follows O
: O
1 O
subject O
( O
3 O
% O
) O
, O
10 O
subjects O
( O
30 O
% O
) O
and O
16 O
subjects O
( O
38 O
% O
) O
in O
the O
untreated O
control O
, O
0 O
. O

23 O
and O
the O
0.47 O
mg/kg/week O
groups O
, O
respectively O
, O
had O
at O
least O
one O
measurement O
; O
while O
0 O
subjects O
( O
0 O
% O
) O
, O
2 O
subjects O
( O
7 O
% O
) O
and O
6 O
subjects O
( O
14 O
% O
) O
had O
two O
or O
more O
consecutive O
IGF-1 O
measurements O
above O
+2 O
SD O
. O

Clinical O
Trials O
in O
adults O
with O
GHD O
In O
clinical O
trials O
with O
GENOTROPIN O
in O
1,145 O
GHD B-Not_AE_Candidate
adults O
, O
the O
majority O
of O
the O
adverse O
events O
consisted O
of O
mild O
to O
moderate O
symptoms O
of O
fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
including O
peripheral B-NonOSE_AE
swelling I-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
pain B-NonOSE_AE
and O
stiffness B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
extremities I-NonOSE_AE
, O
peripheral B-NonOSE_AE
edema I-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
paresthesia B-NonOSE_AE
, O
and O
hypoesthesia B-NonOSE_AE
. O

These O
events O
were O
reported O
early O
during O
therapy O
, O
and O
tended O
to O
be O
transient O
and/or O
responsive O
to O
dosage O
reduction O
. O

Table O
1 O
displays O
the O
adverse O
events O
reported O
by O
5 O
% O
or O
more O
of O
adult O
GHD B-Not_AE_Candidate
patients O
in O
clinical O
trials O
after O
various O
durations O
of O
treatment O
with O
GENOTROPIN O
. O

Also O
presented O
are O
the O
corresponding O
incidence O
rates O
of O
these O
adverse O
events O
in O
placebo O
patients O
during O
the O
6-month O
double-blind O
portion O
of O
the O
clinical O
trials O
. O

Table O
1 O
Adverse O
Events O
Reported O
by O
> O
= O
5 O
% O
of O
1,145 O
Adult O
GHD O
Patients O
During O
Clinical O
Trials O
of O
GENOTROPIN O
and O
Placebo O
, O
Grouped O
by O
Duration O
of O
Treatment O
Double O
Blind O
Phase O
Open O
Label O
PhaseGENOTROPIN O
Adverse O
Event O
Placebo0-6 O
mo.n O
= O
572 O
% O
Patients O
GENOTROPIN0-6 O
mo.n O
= O
573 O
% O
Patients O
6-12 O
mo.n O
= O
504 O
% O
Patients O
12-18 O
mo.n O
= O
63 O
% O
Patients O
18-24 O
mo.n O
= O
60 O
% O
Patients O
n O
= O
number O
of O
patients O
receiving O
treatment O
during O
the O
indicated O
period. O
% O
= O
percentage O
of O
patients O
who O
reported O
the O
event O
during O
the O
indicated O
period O
. O

Swelling B-OSE_Labeled_AE
, I-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
5.1 O
17.5 O
[ O
note O
: O
Increased O
significantly O
when O
compared O
to O
placebo O
, O
P O
< O
=.025 O
: O
Fisher O
's O
Exact O
Test O
( O
one-sided O
) O
] O
5.6 O
0 O
1.7 O
Arthralgia B-OSE_Labeled_AE
4.2 O
17.3 O
6.9 O
6.3 O
3.3 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
14.5 O
15.5 O
13.1 O
15.9 O
13.3 O
Pain B-OSE_Labeled_AE
, I-OSE_Labeled_AE
extremities I-OSE_Labeled_AE
5.9 O
14.7 O
6.7 O
1.6 O
3.3 O
Edema B-OSE_Labeled_AE
, I-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
2.6 O
10.8 O
3.0 O
0 O
0 O
Paresthesia B-OSE_Labeled_AE
1.9 O
9.6 O
2.2 O
3.2 O
0 O
Headache B-OSE_Labeled_AE
7.7 O
9.9 O
6.2 O
0 O
0 O
Stiffness B-OSE_Labeled_AE
of I-OSE_Labeled_AE
extremities I-OSE_Labeled_AE
1.6 O
7.9 O
2.4 O
1.6 O
0 O
Fatigue B-OSE_Labeled_AE
3.8 O
5.8 O
4.6 O
6.3 O
1.7 O
Myalgia B-OSE_Labeled_AE
1.6 O
4.9 O
2.0 O
4.8 O
6.7 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
4.4 O
2.8 O
3.4 O
4.8 O
5.0 O
Post-Trial O
Extension O
Studies O
in O
Adults O
In O
expanded O
post-trial O
extension O
studies O
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
developed O
in O
12 O
of O
3,031 O
patients O
( O
0.4 O
% O
) O
during O
treatment O
with O
GENOTROPIN O
. O

All O
12 O
patients O
had O
predisposing O
factors O
, O
e.g. O
, O
elevated B-Not_AE_Candidate
glycated I-Not_AE_Candidate
hemoglobin I-Not_AE_Candidate
levels I-Not_AE_Candidate
and/or O
marked O
obesity B-Not_AE_Candidate
, O
prior O
to O
receiving O
GENOTROPIN O
. O

Of O
the O
3,031 O
patients O
receiving O
GENOTROPIN O
, O
61 O
( O
2 O
% O
) O
developed O
symptoms O
of O
carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
which O
lessened O
after O
dosage O
reduction O
or O
treatment O
interruption O
( O
52 O
) O
or O
surgery O
( O
9 O
) O
. O

Other O
adverse O
events O
that O
have O
been O
reported O
include O
generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
and O
hypoesthesia B-OSE_Labeled_AE
. O

Anti-hGH O
Antibodies O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
potential O
for O
immunogenicity B-NonOSE_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
GENOTROPIN I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

In O
the O
case O
of O
growth O
hormone O
, O
antibodies B-NonOSE_AE
with O
binding O
capacities O
lower O
than O
2 O
mg/mL O
have O
not O
been O
associated O
with O
growth B-NonOSE_AE
attenuation I-NonOSE_AE
. O

In O
a O
very O
small O
number O
of O
patients O
treated O
with O
somatropin O
, O
when O
binding O
capacity O
was O
greater O
than O
2 O
mg/mL O
, O
interference B-NonOSE_AE
with I-NonOSE_AE
the I-NonOSE_AE
growth I-NonOSE_AE
response I-NonOSE_AE
was O
observed O
. O

In O
419 O
pediatric O
patients O
evaluated O
in O
clinical O
studies O
with O
GENOTROPIN O
lyophilized O
powder O
, O
244 O
had O
been O
treated O
previously O
with O
GENOTROPIN O
or O
other O
growth O
hormone O
preparations O
and O
175 O
had O
received O
no O
previous O
growth O
hormone O
therapy O
. O

Antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
( O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
hGH I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
) O
were O
present O
in O
six O
previously O
treated O
patients O
at O
baseline O
. O

Three O
of O
the O
six O
became O
negative B-OSE_Labeled_AE
for I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
hGH I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
during O
6 O
to O
12 O
months O
of O
treatment O
with O
GENOTROPIN O
. O

Of O
the O
remaining O
413 O
patients O
, O
eight O
( O
1.9 O
% O
) O
developed O
detectable O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
hGH I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
during O
treatment O
with O
GENOTROPIN O
; O
none O
had O
an O
antibody B-NonOSE_AE
binding O
capacity O
> O
2 O
mg/L O
. O

There O
was O
no O
evidence O
that O
the O
growth O
response O
to O
GENOTROPIN O
was O
affected O
in O
these O
antibody B-NonOSE_AE
- I-NonOSE_AE
positive I-NonOSE_AE
patients O
. O

Periplasmic O
Escherichia O
coli O
Peptides O
Preparations O
of O
GENOTROPIN O
contain O
a O
small O
amount O
of O
periplasmic O
Escherichia O
coli O
peptides O
( O
PECP O
) O
. O

Anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
PECP I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
are O
found O
in O
a O
small O
number O
of O
patients O
treated O
with O
GENOTROPIN O
, O
but O
these O
appear O
to O
be O
of O
no O
clinical O
significance O
. O

6.2 O
Post-Marketing O
Experience O
Because O
these O
adverse O
events O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Serious O
systemic B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
angioedema B-OSE_Labeled_AE
have O
been O
reported O
with O
post-marketing O
use O
of O
somatropin O
products O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

Leukemia B-NonOSE_AE
has O
been O
reported O
in O
a O
small O
number O
of O
GHD B-Not_AE_Candidate
children O
treated O
with O
somatropin O
, O
somatrem O
( O
methionylated O
rhGH O
) O
and O
GH O
of O
pituitary O
origin O
. O

It O
is O
uncertain O
whether O
these O
cases O
of O
leukemia B-NonOSE_AE
are O
related O
to O
GH O
therapy O
, O
the O
pathology O
of O
GHD B-Not_AE_Candidate
itself O
, O
or O
other O
associated O
treatments O
such O
as O
radiation O
therapy O
. O

On O
the O
basis O
of O
current O
evidence O
, O
experts O
have O
not O
been O
able O
to O
conclude O
that O
GH O
therapy O
per O
se O
was O
responsible O
for O
these O
cases O
of O
leukemia B-NonOSE_AE
. O

The O
risk O
for O
children O
with O
GHD B-Not_AE_Candidate
, O
if O
any O
, O
remains O
to O
be O
established O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

The O
following O
serious O
adverse O
reactions O
have O
been O
observed O
with O
use O
of O
somatropin O
( O
including O
events O
observed O
in O
patients O
who O
received O
brands O
of O
somatropin O
other O
than O
GENOTROPIN O
) O
: O
acute B-OSE_Labeled_AE
critical I-OSE_Labeled_AE
illness I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
, O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
, O
intracranial B-OSE_Labeled_AE
tumors I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
, O
central B-OSE_Labeled_AE
hypothyroidism I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
, O
cardiovascular B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
and O
pancreatitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
. O

Slipped B-OSE_Labeled_AE
capital I-OSE_Labeled_AE
femoral I-OSE_Labeled_AE
epiphysis I-OSE_Labeled_AE
and O
Legg B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Calve I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Perthes I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
osteonecrosis B-OSE_Labeled_AE
/ O
avascular B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
; O
occasionally O
associated O
with O
slipped B-OSE_Labeled_AE
capital I-OSE_Labeled_AE
femoral I-OSE_Labeled_AE
epiphysis I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
children O
treated O
with O
growth O
hormone O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
. O

Cases O
have O
been O
reported O
with O
GENOTROPIN O
. O

The O
following O
additional O
adverse O
reactions O
have O
been O
observed O
during O
the O
appropriate O
use O
of O
somatropin O
: O
headaches B-OSE_Labeled_AE
( O
children O
and O
adults O
) O
, O
gynecomastia B-OSE_Labeled_AE
( O
children O
) O
, O
and O
significant B-OSE_Labeled_AE
diabetic I-OSE_Labeled_AE
retinopathy I-OSE_Labeled_AE
. O

New-onset O
type B-OSE_Labeled_AE
2 I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
has O
been O
reported O
. O

